Valneva SE

VALN | NASDAQ

Price Alert Chart Builder DCF Calculator

$6.62

+$0.06 (+0.91%)

At close: Sep 21, 2026, 4:00 PM ET

$6.62

$0 (0.00%)

After-hours: Sep 21, 2026, 4:10 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.91%

(1D)

Rating

Updated: Aug 20, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $627.73M

1D Range

6.57 6.68

52W Range

4.75 12.23

Valuation (TTM)

PE -3.12

PB 6.78

EV/EBITDA -6.77

Valuation (NTM)

Forward PE 11.21

Forward PEG 0.02

Price Target $11

Cash Flow

FCF Yield -15.7%

SBC Adj. FCF Yield -15.7%

SBC Impact N/A

Margins

Gross Margin 16.4%

Operating Margin -80.9%

FCF Margin -59.7%

Growth (CAGR)

Revenue 3Y | 5Y -25.1% | 5.5%

Dil EPS 3Y | 5Y -61.1% | 14.9%

FCF 3Y | 5Y 60.8% | 24.6%

Returns

ROA -40.6%

ROE -152.2%

ROIC -40.5%

Financial Health

Net Debt

€65.24M ($74.51M)

Current Ratio 2.16

Interest Coverage -3.05

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Valneva SE operates as a specialized biopharmaceutical company, concentrating its efforts on developing and bringing to market preventative vaccines for infectious diseases where current medical optio...

Sector Healthcare

Industry Biotechnology

Employees 674

IPO Date May 4, 2021

Website valneva.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 19, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Sell

Price Target

$11

Upside

+66.16%

Buy (0)

Hold (0)

Sell (1)

Analyst Details ➞